Press Release: Mergers: Commission approves proposed creation of joint venture between Lonza and Teva

The European Commission has cleared under the EU Merger Regulation the proposed creation of a joint venture to be active in the biosimilar industry, between the two pharmaceutical companies Lonza of Switzerland and Teva of Israel. Biosimilars are the generic equivalent of drugs produced using biological processes. The Commission concluded that the transaction would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it.